Related Experiment Video
Updated: Apr 29, 2026

Peptide and Protein Quantification Using Automated Immuno-MALDI iMALDI
Published on: August 18, 2017
Performance and additional benefits of MALDI-TOF-MS in M-protein detection in plasma cell disorders
Mengmeng Dong1, Hongying Ye1, Xiao Xiao2
1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Purposes:
Current methods for detecting monoclonal (M) proteins, such as immunofixation electrophoresis (IFE), serum protein electrophoresis (SPEP) and serum free light chains (sFLC), are limited by insufficient sensitivity and suboptimal efficiency. This study evaluated the performance and supplementary value of matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) for the detection of M-protein.
Methods:
The M protein in the blood samples of 137 newly diagnosed plasma cell disorder (PCD) patients were detected using MALDI-TOF-MS. Using SPEP/IFE/sFLC as the gold standard, the performance of MALDI‑TOF MS was assessed; discrepant results were confirmed by urine IFE.
Results:
The cohort included multiple PCD subtypes, detailly, 116 multiple myeloma (MM, 84.7%), 7 amyloid light-chain (AL) amyloidosis (5.1%), 6 MM combined with AL amyloidosis (4.4%), 4 monoclonal gammopathy of undetermined significance (MGUS, 2.9%), and others. Serum-based MALDI-TOF-MS demonstrated a high detection rate for M-protein identification compared to SPEP, serum IFE, sFLC and urine IFE (98.5% vs. 75.9% vs. 86.9% vs. 71.5% vs. 76.0%). Plasma-based testing achieved a concordance rate of 89.1% (122/137). Using IFE/sFLC results as the gold standard, the sensitivity of MALDI-TOF-MS for the identification of κ and λ light chains (LC) was 75.8% and 80.0%, respectively. For IgG and IgA identification, the sensitivity of MALDI-TOF-MS was 93.5% (58/62) and 65.5% (19/29), respectively. Additionally, MALDI-TOF-MS detected LC glycosylation in 17 patients and other post-translational modifications (PTMs) in 4 patients. Notably, post-treatment monitoring revealed that two patients with eliminated glycosylation peaks achieved complete response, while one with persistent glycosylation had a very good partial response.
Conclusions:
MALDI-TOF-MS is a reliable tool for M-protein detection, offering high detection rate, LC glycosylation identification, and PTM analysis. Additionally, in a small cohort, we observed that changes in the abnormal peaks detected by MALDI-TOF-MS may correlate with treatment response.
Insights
Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) offers a highly sensitive method for detecting monoclonal (M) proteins in plasma cell disorders. This advanced technique also identifies glycosylation and post-translational modifications, potentially correlating with treatment response.
Area of Science:
- Clinical Chemistry
- Mass Spectrometry
- Oncology
Background:
- Current monoclonal (M) protein detection methods like immunofixation electrophoresis (IFE), serum protein electrophoresis (SPEP), and serum free light chains (sFLC) have limitations in sensitivity and efficiency.
- Plasma cell disorders (PCD) require accurate M-protein detection for diagnosis and monitoring.
Purpose of the Study:
- To evaluate the performance and supplementary value of matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) for M-protein detection.
- To compare MALDI-TOF-MS with existing diagnostic methods for PCD.
Main Methods:
- M-protein detection in 137 newly diagnosed PCD patients using MALDI-TOF-MS.
- Comparison of MALDI-TOF-MS results against SPEP, IFE, and sFLC as the gold standard.
- Confirmation of discrepant results using urine IFE.
- Analysis of sensitivity for light chains (κ, λ) and heavy chains (IgG, IgA).
Main Results:
- MALDI-TOF-MS demonstrated a high M-protein detection rate (98.5%) compared to SPEP (75.9%), serum IFE (86.9%), sFLC (71.5%), and urine IFE (76.0%).
- The sensitivity of MALDI-TOF-MS for κ and λ light chains was 75.8% and 80.0%, respectively; for IgG and IgA, it was 93.5% and 65.5%.
- MALDI-TOF-MS identified LC glycosylation in 17 patients and other post-translational modifications (PTMs) in 4 patients, with observed correlations between glycosylation changes and treatment response.
Conclusions:
- MALDI-TOF-MS is a reliable tool for M-protein detection, offering high sensitivity and the capability to identify LC glycosylation and PTMs.
- Observed correlations between abnormal peak changes detected by MALDI-TOF-MS and treatment response suggest its potential utility in monitoring therapy effectiveness.
More Related Videos
13:00Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery
Published on: April 17, 2012
07:49Matrix-assisted Laser Desorption/Ionization Time of Flight MALDI-TOF Mass Spectrometric Analysis of Intact Proteins Larger than 100 kDa
Published on: September 9, 2013
Related Concept Videos
MALDI-TOF Mass Spectrometry
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Matrix-Assisted Laser Desorption Ionization (MALDI)
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...